NewGenIVF Converts Project to Joint Development, Expected Profit Increases to $123 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2025
0mins
Source: Newsfilter
- Profit Enhancement: NewGenIVF plans to convert the Ras Al Khaimah project structure from a joint venture to a joint development, expecting to increase its pre-tax profit from $67 million to $123 million, demonstrating strong confidence in the project's profitability.
- Increased Financial Flexibility: Under the new structure, NewGenProperty Limited will assume full responsibility for project financing, ensuring a 64% share of net profits, which enhances the company's financial flexibility to accelerate development activities.
- Market Opportunity Capture: With the rapid appreciation of the Ras Al Khaimah real estate market, NewGen plans to raise additional funds to support the project conversion, which is expected to generate significant presale proceeds and reduce external funding needs.
- Legal Compliance Assurance: The conversion option has been confirmed by a leading law firm, ensuring that NewGen has the legal right to execute this conversion, thereby enhancing the transaction's legality and enforceability.
Analyst Views on NIVF
About NIVF
NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. It specializes in in-vitro fertilization (IVF) treatment and surrogacy and ancillary caring services. Its fertility treatments, such as IVF, intracytoplasmic sperm injection, intrauterine insemination, egg freezing, embryo transfer, gender selection, semen analysis, hysteroscopy, fertility checkups, testicular sperm aspiration and percutaneous epididymal sperm aspiration. Its clinics are in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. It has acquired cytometry technology and assets including 18 fully constructed cell-sorting and dispensing systems, eight partially constructed units and six patents related to advanced microfluidic systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
